Correlate genotype and immunophenotype with ex vivo drug response in primary patient samples. Evaluate whether a candidate marker reflects biological activity and develop enrichment hypotheses for subsequent clinical trials.
The presence of a target does not necessarily indicate cellular dependence. Most heme biomarkers are prognostic and describe disease behavior rather than predicting drug efficacy.
xCellSense® measures genotype, immunophenotype, and drug response within the same primary patient sample. This ensures that any association reflects the patient's biology rather than donor variability.
Marker profiling
Mutation status by targeted NGS and immunophenotype by flow cytometry are both profiled in the same primary sample used for drug testing.
Ex vivo drug response
IC₅₀, AUC, and Eₘₐₓ for your asset in live primary cells — the response variable each candidate marker is tested against.
Marker–response associationCDx rationale
Effect size and confidence intervals for the association between biomarker status and measured ex vivo response — separating predictive markers from prognostic ones.
Enrichment hypotheses
Candidate inclusion criteria for prospective testing, with the effect sizes supporting each — hypotheses to test, not selection rules to apply."
Enriching on a marker that does not predict response narrows your population without improving your odds, and most heme biomarkers are prognostic. Functional characterization tests the assumption before it becomes an inclusion criterion. It sharpens enrichment, supports designs needing fewer patients to detect a signal, and strengthens the translational rationale for protocols and partners.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
